BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2020 7:33:17 AM | Browse: 1017 | Download: 2100
 |
Received |
|
2020-04-13 13:15 |
|
Peer-Review Started |
|
2020-04-13 13:16 |
|
First Decision by Editorial Office Director |
|
2020-04-28 04:05 |
|
Return for Revision |
|
2020-04-28 04:05 |
|
Revised |
|
2020-05-05 13:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-05-20 11:14 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-05-21 02:53 |
|
Articles in Press |
|
2020-05-21 02:53 |
|
Edit the Manuscript by Language Editor |
|
2020-05-26 00:06 |
|
Typeset the Manuscript |
|
2020-06-19 01:59 |
|
Publish the Manuscript Online |
|
2020-06-24 07:33 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Successful treatment plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jian Chen, Jing-Xia Jin, Xiao-Fei Xu, Xuan-Xuan Zhang, Xing-Nong Ye and Jian Huang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Public Technology Research Projects of Yiwu, China |
No. 2016S05 |
| the Key Project of Jinhua Science and Technology Plan |
No. 2020XG-29 |
| the 2018-2020 Key Medical Discipline (Hematology) Fund of Yiwu, China |
|
| the 2019-2021 Key Medical Discipline (Hematology) Fund of Jinhua, China |
|
| the Project of Educational Commission of Zhejiang Province of China |
No. Y201942124 |
| the 2019-2024 Academician Workstation Fund of the Fourth Affiliated Hospital of Zhejiang University School of Medicine |
|
|
| Corresponding Author |
Jian Huang, PhD, Chief Physician, Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, No. 1 Shangcheng Road, Yiwu 322000, Zhejiang Province, China. househuang@zju.edu.cn |
| Key Words |
Thrombotic thrombocytopenic purpura; ADAMTS13; Plasma exchange; Rituximab; Case report; |
| Core Tip |
Thrombotic thrombocytopenic purpura (TTP) has a very high fatality rate if there is no timely diagnosis and treatment. Here we report a case of refractory TTP in a woman with decreased ADAMTS13 activity. Although the patient was refractory to daily plasma exchange, her platelet count and ADAMTS13 activity returned to normal after 6 d of treatment with rituximab. This case suggested that rituximab can improve the curative efficiency of plasma exchange in TTP. |
| Publish Date |
2020-06-24 07:33 |
| Citation |
Chen J, Jin JX, Xu XF, Zhang XX, Ye XN, Huang J. Successful treatment plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report. World J Clin Cases 2020; 8(12): 2617-2622 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i12/2617.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i12.2617 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
